Flagship Pioneering and Repertoire Immune Medicines Partner with Pfizer to Develop TCR Bispecifics for Metastatic Prostate Cancer
核心洞察
Flagship Pioneering (搜索) announced a research program with Repertoire Immune Medicines (搜索) to identify and optimize T cell receptor bispecifics (搜索) for metastatic prostate cancer (搜索) under their strategic partnership with Pfizer.
The collaboration leverages Repertoire's DECODE platform to map the entire immune synapse (搜索) and discover new antigens (搜索) capable of activating the immune system to fight cancer (搜索).
As many as one in five men with prostate cancer (搜索) progress to metastatic disease with many developing resistance to successive therapy lines, creating an urgent need for new treatment approaches.
Flagship Pioneering (搜索) announced a new research program with its portfolio company Repertoire Immune Medicines (搜索) to develop T cell receptor (TCR) bispecifics for metastatic prostate cancer (搜索), conducted under the venture capital firm's strategic collaboration with Pfizer. The initiative represents the eighth program launched since Flagship and Pfizer established their partnership in July 2023.
Addressing Unmet Medical Need in Metastatic Prostate Cancer
The collaboration targets a significant clinical challenge, as up to one in five men with prostate cancer (搜索) progress to metastatic disease, with many subsequently developing resistance to successive lines of therapy. TCR bispecifics (搜索) have emerged as a promising immunotherapy (搜索) approach with the potential to overcome several barriers associated with disease progression.
"As many as one in five men with prostate cancer (搜索) progress to metastatic disease with many going on to develop resistance to successive lines of therapy," the companies stated. The research program aims to identify and develop an early optimized TCR bispecific lead that could provide durable disease control and reduced toxicity.
Leveraging DECODE Platform Technology
Repertoire's proprietary DECODE platform will serve as the foundation for the research activities, conducted jointly with Pioneering Medicines (搜索), Flagship's in-house drug development unit. The platform uniquely maps the entire immune synapse (搜索), providing comprehensive understanding of interactions between T cell receptors (搜索) and their cognate antigenic epitopes (搜索).
"Repertoire's DECODE platform uniquely maps the entire immune synapse (搜索), presenting enormous uncharted potential to discover new antigens (搜索) capable of activating the immune system to fight cancer (搜索)," said Torben Straight Nissen, Ph.D., Chairman and CEO of Repertoire and Executive Partner at Flagship Pioneering (搜索). "When coupled with Repertoire's immune medicine engineering technologies and capabilities, places us in a strong position to generate targeted medicines to engage them."
Strategic Partnership Expansion
The agreement demonstrates the continued momentum of Flagship's strategic alliance with Pfizer, which now encompasses eight programs across multiple modalities and five therapeutic areas. Pioneering Medicines (搜索) leads the strategic partnership with Pfizer, driving the exploration process to rapidly surface potential drug development programs built on Flagship's diverse bioplatforms and modalities.
"This research program with Repertoire demonstrates both the continued momentum in our strategic alliance with Pfizer and the breadth of novel modalities our Flagship companies offer as a supply chain of potential therapeutic innovation," said Paul Biondi, Flagship Pioneering (搜索) Managing Partner. "We have now collaborated on eight programs across multiple modalities and five therapeutic areas in our shared commitment with Pfizer to co-create a pipeline of novel candidates that have a potential to become differentiated medicines with greater precision, speed, and scale for the patients who need them most."
Company Background and Platform Capabilities
Repertoire Immune Medicines (搜索), founded in 2019 by Flagship Pioneering (搜索), focuses on discovering immune codes that determine health maintenance and disease response. The company operates from sites in Cambridge, Massachusetts and Zurich, translating insights from its DECODE platform into T cell-targeted therapies for cancer (搜索) and autoimmune diseases (搜索).
Flagship Pioneering (搜索), launched in 2000, has originated and fostered more than 100 scientific ventures, operating with $14 billion of assets under its direction as of its latest capital raise announced in July 2024. The current Flagship ecosystem comprises more than 40 companies, including notable ventures such as Moderna, Sana Biotechnology, and Tessera Therapeutics.